CA - Tetra Cellvera team up to develop ARDS-003/favipiravir combo for COVID-19

Tetra Bio-Pharma ( OTCQB:TBPMF ) and Cellvera Global Holdings are collaborating to develop oral drug ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), to treat patients with COVID-19.

Tetra said Cellvera owns the rights to the brand originator Favipiravir.

As a monotherapy, compared to placebo, ARDS-003 dose-dependently reduced signs of morbidity and mortality, including respiratory distress following COVID-19 infection in the humanized ACE2 mouse model, Tetra said in a Sept. 6 press release.

The company added that ARDS-003 also outperformed an antiviral drug in reducing multiple proinflammatory mediators (i.e., cytokines) involved in hyperinflammation and immune system dysfunction following viral infection.

For further details see: